MARLBOROUGH, Mass.,
April 27, 2015 /PRNewswire/
-- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a
biotechnology company focused on discovering and developing
innovative therapies primarily in the areas of dermatology and
ophthalmology, today announced several oral and poster
presentations at leading partnering and scientific conferences on
May 4, 6, 7 and 9, 2015.
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
BioNetwork Partnering Summit
On Monday, May 4, 2015 from
12:05 to 12:20 p.m. EDT, Dr.
Geert Cauwenbergh, Dr. Med. Sc.,
RXi's President and CEO, will present a corporate overview,
including multiple business development opportunities available
based on RXi's proprietary sd-rxRNA® platform and
extensive intellectual property portfolio. The presentation
will be available on the Company's website at www.rxipharma.com
approximately one hour after the presentation.
Now in its 12th year, the BioNetwork Partnering
Summit has been providing a platform for business development
executives across the pharmaceutical and biotechnology space to
come together in an intimate setting and develop relationships that
may lead to strategic partnerships. This conference is being held
May 4-6, 2015 at the Trump
International Beach Resort Miami, Sunny
Isles Beach, FL.
Association for Research in Vision and Ophthalmology (ARVO)
2015 Annual Meeting
On Wednesday, May 6, 2015 in the
8:30 to 10:15 a.m. MDT poster
session, data from an ongoing research collaboration between RXi
Pharmaceuticals and Jade Therapeutics, on work in the area of
corneal drug delivery to reduce scar formation, will be presented.
These data may be viewed on Poster 4143-C0026 entitled,
"Formulation and Release of sd‑rxRNA® from a
Cross-linked, Thiolated CMHA-based Film for Topical Delivery to
Reduce the Formation of Corneal Scarring," presented during session
416.
On Thursday, May 7, 2015 in the
8:30 to 10:15 a.m. MDT poster
session, data will be presented from a research collaboration, in
the area of retinoblastoma, between RXi Pharmaceuticals and
David Cobrinik, M.D., Ph.D.,
Principal Investigator at The Saban Research Institute of
Children's Hospital Los Angeles. These data may be viewed on Poster
5473-B0032 entitled, "MDM2 Targeting sd‑rxRNA® for
Retinoblastoma Therapy," presented during session 509.
Both posters will be available on the Company's website at
www.rxipharma.com approximately one hour after each
presentation.
The Annual Meeting of ARVO is the largest gathering of eye and
vision researchers in the world, attracting over 11,000 attendees
from more than 75 countries. ARVO is being held May 3-7, 2015 at the Colorado Convention Center, Denver, Colorado.
IBCs 17th Annual TIDES: Oligonucleotide and
Peptide Therapeutics from Research through
Commercialization
On Wednesday, May 6, 2015 at
11:45 a.m. PDT, Karen Bulock, Ph.D., RXi's Vice President of
Research, will present an overview of the Company's dermal clinical
program with RXI-109. The oral presentation entitled, "Clinical
Development of RXI-109 to Prevent Dermal Scarring," will take
place during the Clinical Updates on Oligonucleotides
session. Dr. Bulock's presentation will be available on the
Company's website at www.rxipharma.com approximately one hour after
the presentation.
The TIDES Summit is prominently known as the premier meeting
place for CMC, clinical and discovery scientists to accelerate
product development. This meeting is being held May 3-6, 2015 at the Town and Country Resort,
San Diego, CA.
Society for Investigative Dermatology (SID) 74th
Annual Meeting
On Saturday, May 9, 2015, in the
10:00 a.m. to 12:00 p.m. EDT poster
session, data will be presented on the Company's ongoing work with
our sd-rxRNA® compounds that target Collagenase (MMP1),
a key enzyme involved in the breakdown of the extracellular matrix.
MMP1-targeting compounds may potentially be beneficial in a number
of therapeutic areas including skin aging disorders, arthritis,
acne scarring and possibly cancer metastasis. These data may
be viewed on Poster 487 entitled, "Self-delivering RNAi Compounds
Targeting Collagenase," during the Growth Factors, Cell Adhesion
and Matrix Biology session.
On Saturday, May 9, 2015, in the
10:00 a.m. to 12:00 p.m. EDT poster
session, data will be presented on the Company's ongoing work with
our sd-rxRNA® compounds that target Tyrosinase (TYR), a
key enzyme in the synthesis of melanin. TYR-targeting compounds may
be therapeutically useful in a number of areas including cutaneous
hyperpigmentation disorders such as age spots, liver spots,
freckles and potentially melanoma. These data may be viewed on
Poster 642 entitled, "Tyrosinase Targeting Self-delivering RNAi
Compounds," during the Pigmentation and Melanoma
session.
Both posters will be available on the Company's website at
www.rxipharma.com approximately one hour after each
presentation.
The SID mission is to advance and promote the sciences relevant
to skin health and disease through education, advocacy and
scholarly exchange of scientific information. This annual meeting
is being held May 6-9, 2015 at the
Hilton Atlanta, Atlanta, GA.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company focused on discovering and developing
innovative therapeutics primarily in the area of dermatology and
ophthalmology that address high-unmet medical needs. Our discovery
and clinical development programs are based on siRNA technology as
well as immunotherapy agents. These compounds include, but are
not limited to, our proprietary, self-delivering RNAi
(sd-rxRNA®) compounds for the treatment of dermal and
retinal scarring. It also includes an immunomodulator, Samcyprone™,
a proprietary topical formulation of diphenylcyclopropenone (DPCP),
for the treatment of such disorders as alopecia areata, warts, and
cutaneous metastases of melanoma.
RXi's robust pipeline, coupled with an extensive patent
portfolio, provides for product and business development
opportunities across a broad spectrum. We are committed to being a
partner of choice for academia, small companies, and large
multinationals. We welcome ideas and proposals for strategic
alliances, including in- and out-licensing opportunities, to
advance and further develop strategic areas of interest. Additional
information may be found on the Company's website,
www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. These statements include, but are not limited to, statements
about future expectations and planned and future development of our
product candidates, technologies and partnerships.
Forward-looking statements about expectations and development
plans of RXi's product candidates and partnerships involve
significant risks and uncertainties, including the following: risks
that we may not be able to successfully develop and commercialize
our product candidates; risks that product development and clinical
studies may be delayed, not proceed as planned and/or be subject to
significant cost over-runs; risks related to the development and
commercialization of products by competitors; risks related to our
ability to control the timing and terms of collaborations with
third parties; and risks that other companies or organizations may
assert patent rights preventing us from developing or
commercializing our product candidates. Additional risks are
detailed in our most recent Annual Report on Form 10-K and
subsequent Quarterly Reports on Form 10-Q under the caption "Risk
Factors." Readers are urged to review these risk factors and
to not act in reliance on any forward-looking statements, as actual
results may differ from those contemplated by our forward-looking
statements. RXi does not undertake to update forward-looking
statements to reflect a change in its views, events or
circumstances that occur after the date of this release.
Contact
RXi Pharmaceuticals Corporation
Tamara McGrillen
508-929-3646
tmcgrillen@rxipharma.com
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/rxi-pharmaceuticals-announces-upcoming-presentations-at-leading-partnering-and-scientific-conferences-300072089.html
SOURCE RXi Pharmaceuticals Corporation